Corebridge Financial Inc. Has $5.47 Million Position in Insulet Corporation $PODD

Key Points

• Corebridge Financial Inc. increased its stake in Insulet Corporation by 12.2% during the first quarter, bringing its total holdings to 20,844 shares valued at $5,474,000.
• Institutional investors have shown significant interest in Insulet, with Allspring Global Investments and Farther Finance Advisors increasing their positions by 55.5% and 85.1% respectively in the same quarter.
• Wall Street analysts have upgraded Insulet's stock ratings, with a consensus price target of $332.71 and 16 analysts recommending a "Buy" rating.

Corebridge Financial Inc. lifted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 12.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,844 shares of the medical instruments supplier's stock after purchasing an additional 2,266 shares during the quarter. Corebridge Financial Inc.'s holdings in Insulet were worth $5,474,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of PODD. Susquehanna Fundamental Investments LLC purchased a new position in Insulet in the fourth quarter valued at about $371,000. Freestone Grove Partners LP acquired a new stake in shares of Insulet during the 4th quarter valued at about $416,000. Itau Unibanco Holding S.A. bought a new stake in shares of Insulet in the 4th quarter valued at approximately $42,000. Wahed Invest LLC increased its holdings in Insulet by 4.1% in the fourth quarter. Wahed Invest LLC now owns 1,766 shares of the medical instruments supplier's stock worth $461,000 after buying an additional 70 shares during the last quarter. Finally, BLI Banque de Luxembourg Investments bought a new position in Insulet during the fourth quarter valued at approximately $13,749,000.

Analysts Set New Price Targets

Several research firms have weighed in on PODD. Canaccord Genuity Group raised their target price on Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a report on Friday, August 8th. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Citigroup reissued a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Oppenheimer raised their price objective on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Price Performance

PODD traded up $2.83 during midday trading on Thursday, reaching $346.36. 230,311 shares of the company's stock were exchanged, compared to its average volume of 753,441. Insulet Corporation has a one year low of $211.27 and a one year high of $350.00. The firm has a market capitalization of $24.38 billion, a price-to-earnings ratio of 105.28, a price-to-earnings-growth ratio of 2.85 and a beta of 1.36. The business has a 50-day simple moving average of $306.11 and a two-hundred day simple moving average of $288.90. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter last year, the company earned $0.55 EPS. Insulet's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.